Cancer Archives

nsclc cancer vaccine immunotherapy opdivo combo

News and Trends 17 Aug 2016

Bavarian Nordic gets hold of Opdivo for new Combination Phase II trial

Just after a major clinical failure, BMS is now shipping Opdivo to Bavarian Nordic for a Phase II trial. Sponsored by Bavarian Nordic, the planned trial will evaluate the combination of a cancer vaccine and the anti-PD-L1 checkpoint inhibitor. Checkpoint blocking has generated a lot of excitement in cancer treatments as part of the immuno-oncology […]

August 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Aug 2016

How did Cancer Cell Therapy become reality?

Using the body’s own tools to eradicate cancers has been a dream of Medicine for quite some time. How did the field of immuno-oncology evolve into today’s Biotech hype? The near-miraculous results of immuno-oncology cell therapies have dominated news about cancer breakthroughs. Indeed, CAR-T is a game-changer and are at the forefront of the ways Biotech […]

August 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

entrechem oviedo secondary metabolite engineering

News and Trends 12 Aug 2016

EntreChem is going Back to the Future of Drug Discovery

We leave the Netherlands with a smile after visiting FF Pharma in Utrecht this week. Once again, we depart to another part of Europe and this time we’re heading to the North of Spain. Oviedo, the main capital of the Spanish Asturias region, is our final destination and is also where EntreChem, our Biotech of the […]

August 12, 2016 - 2 minutesmins - By Joachim Eeckhout

astrazeneca phase III failure nsclc selumetinib

News and Trends 11 Aug 2016

This new Phase III Failure adds up to AstraZeneca’s Troubles

AstraZeneca’s oncology pipeline takes a hit, as one of its Phase III trials failed to meet its primary endpoint. The program targeted advanced non-small lung cancer. It looks like it’s up to immunotherapies now. Now struggling for a while, AstraZeneca has been refocusing on cancer and investing big in new candidates. The strategy hasn’t yet […]

August 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 4 Aug 2016

Marine Drug goes to Phase III trials to treat Lung Cancer

PharmaMar is starting a new Phase III trial, with patients suffering from small cell lung cancer (SCLC). It’ll test the efficacy of its third candidate obtained from marine organisms (PM1183) as a SCLC treatment. PharmaMar is one of the hot Biotechs in Spain, which just saw its second drug finish Phase III trials with good results (and is […]

August 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

Best in Biotech 2 Aug 2016

7 Books to turn you into a Biotech Genius over the Summer

As summer is approaching its peak, we thought that you would like to discover some of the Biotech books we love the most. This list (without any particular order) will give you a broad choice of topics, from entrepreneurial journeys to scientific breakthroughs. Enjoy reading and be inspired by these amazing stories! The Antidote: Inside the […]

August 2, 2016 - 4 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2016

Philogen targets Angiogenesis for cancer and Autoimmune Therapies

Barcelona was pleasant but once again it’s time to go away! We won’t go far… we’re just crossing the Balearic sea to the shores of Italy and visit Sovicille, a suburban town not far from Sienna, where Swiss-Italian company Philogen, our Biotech of the Week, is based! City: Sovicille (Italy) Founded: 1996 Employees: 70 Financial Data: N/A CEO: Duccio […]

July 29, 2016 - 2 minutesmins - By Joachim Eeckhout

cancer hypoxia antimalarial drug atovaquone

News and Trends 26 Jul 2016

This Malaria drug is being re-purposed for Cancer Radiotherapy

Cancer Research UK says an old anti-malaria drug could be repurposed as a cancer therapy. In pre-clinical studies, this drug increases oxygen levels in tumors, making them easier to treat with radiotherapy. Atovaquone has been on the market since 2000 as part of an anti-malarial drug. It is also commercialized by GSK under the name Mepron for […]

July 26, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Jul 2016

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach. City: Barcelona (Spain) Founded: 2000 Employees: 35 Financial Data: €81.50M Market Cap (Bolsa de […]

July 22, 2016 - 2 minutesmins - By Joachim Eeckhout

car t cd19 fda juno therapeutics cerebral edema

News and Trends 18 Jul 2016

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after 3 deaths, which could be treatment-related. How will this impact the field, given that most CAR-T Biotechs share the same target? UPDATE (article originally published on 8/7/2016): the FDA has allowed Juno Therapeutics to resume its CAR-T trial with […]

July 18, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 15 Jul 2016

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field. Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and […]

July 15, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 15 Jul 2016

Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

Israel, we’re on our way! We leave Denmark with a smile and head down to sunny Tel-Aviv, where Compugen, a big Israeli-based leading drug discovery company and our Biotech of The Week, is located. City: Tel-Aviv (Israel) Founded: 1993 Employees: 93 (as of 03/2016) Financial Data: €257.2M Market Cap (on 22/03/2016) CEO: Anat Cohen-Dayan Mission: Compugen-discovered drug targets are primarily […]

July 15, 2016 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Bavarian Nordic gets hold of Opdivo for new Combination Phase II trial

How did Cancer Cell Therapy become reality?

EntreChem is going Back to the Future of Drug Discovery

This new Phase III Failure adds up to AstraZeneca’s Troubles

Marine Drug goes to Phase III trials to treat Lung Cancer

7 Books to turn you into a Biotech Genius over the Summer

Philogen targets Angiogenesis for cancer and Autoimmune Therapies

This Malaria drug is being re-purposed for Cancer Radiotherapy

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!